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Abstract
Although there have been significant advances in the adjuvant therapy of colorectal cancer, results for patients
have historically been poor when complete resection is unlikely or not possible. Similarly, locally recurrent colorectal
cancer patients often experience significant tumor related morbidity and disease control and long term survival
have historically been poor with standard therapies. Intraoperative radiation therapy (IORT) has been proposed as a
possible tool for dose escalation in patients with locally advanced colorectal cancer.
For patients with locally advanced primary or recurrent colon cancer, the absence of prospective controlled trials
limits the ability to draw definitive conclusions in completely resected patients. In subtotally resected patients, the
available evidence is consistent with marked improvements in disease control and survival compared to historical
controls. For patients with locally advanced primary or recurrent rectal cancer, a relatively large body of evidence
suggests improved disease control and survival, especially in subtotally resected patients, with the addition of IORT
to moderate dose external beam radiation (EBRT) and chemotherapy. The most important prognostic factor in nearly
all series is the completeness of surgical resection. Many previously irradiated patients may be carefully re-treated with
radiation and IORT in addition to chemotherapy resulting in long term survival in more than 25% of patients. Peripheral
nerve is dose limiting for IORT and patients receiving 15 Gy or more are at higher risk.
IORT is a useful tool when dose escalation beyond EBRT tolerance limits is required for acceptable local control in
patients with locally advanced primary or recurrent colorectal cancer. Previously irradiated patients should not be
excluded from treatment consideration.
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Introduction
Despite the realized therapeutic gains, colorectal cancer
remains the 5th leading cause of cancer death in the
world with more than 1 million new cases and more
than 600,000 deaths per year [1]. Screening for colorec-
tal cancer is an effective tool and where implemented
has resulted in declines in cancer mortality [2]. When
diagnosed at an early stage, the prognosis following sur-
gical based treatment of colorectal cancer is excellent.
However, for patients with locally advanced primary or
recurrent colon cancer, often unresectable for cure, re-
currence rates are high and survival is poor with con-
ventional therapy [3]. Similarly, very locally advanced
primary or recurrent rectal cancer patients have high
rates of local and distant relapse and poor survival out-
comes [4–6].
The concept of using radiation therapy during an op-
eration to treat a malignancy originated more than
100 years ago and early investigations took place in
Spain, Austria, Germany and the United States [7]. One
of the earliest reports of the use of intraoperative radi-
ation therapy (IORT) for treatment of rectal cancer
using orthovoltage was reported by Stanford investiga-
tors in 1937 [8]. Investigation of IORT in the megavol-
tage era using high energy electrons or began in the
1980s with more than 100 reports on the use of IORT
for colorectal cancer published in the last 20 years. The
majority of reports are single institution retrospective
series and very few prospective studies have been per-
formed. This review will summarize the results of IORT
investigations for treatment of primary or recurrent
colorectal cancer in the megavoltage era.
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IORT rationale
Historically, radiation dose fractionation schemes used
to treat colorectal cancer were based more on normal
tissue tolerance doses than on consideration of bio-
logical effective dose needed to control tumor. In the ab-
domen and pelvis, small bowel is typically the dose
limiting normal tissue. Doses exceeding 45–50 Gy in
1.8–2 Gy fractions to a significant volume of small bowel
are associated with a greater than 5% risk of late stric-
ture or ulceration [9]. QUANTEC guidelines suggest
that not more than 195 cc of peritoneal space that may
potentially contain small bowel receive greater than
45 Gy [10]. Doses of 45–50 Gy, standardly fractionated
with concomitant 5-FU have been shown in multiple
phase III trials to be effective in reducing the risk of
local relapse when combined with R0 surgical resection
[11, 12]. However, when chemoradiation is combined
with an R1 or R2 resection for locally advanced primary
or recurrent rectal cancer, 45–50 Gy has been largely in-
effective in achieving local control.
Retrospective data suggest that doses well in excess of
50 Gy are required for control of microscopic or gross
colorectal cancer. In the Mayo Clinic experience, doses
of 40–60 Gy following subtotal resection of rectal cancer
resulted in 70% local relapse in patients with micro-
scopic residual disease and 86% local relapse in patients
with gross residual disease [13]. In a small series from
Massachusetts General Hospital there was evidence of a
dose response in patients with subtotally resected rectal
cancer. Following R1 resection, local failure was ob-
served in 40% of patients who received 50–60 Gy, but
only 11% in those who received > 60 Gy. For patients
with gross residual disease, even doses of 60–70 Gy were
not effective with local relapse observed in 67% of pa-
tients [14]. In a small prospective Mayo Clinic trial a
dose of 50 Gy for unresectable, residual or recurrent
colorectal cancer was associated with progression in the
radiation field in 90% of patients [15]. Small bowel ob-
struction was observed in 16% of patients.
Modern prospective trials have confirmed the inef-
fectiveness of moderate dose radiation therapy to con-
trol residual colorectal cancer. In the MRC CR07 trial,
a short course of 25 Gy in 5 fractions preoperatively
was compared to surgical resection alone with postop-
erative chemoradiation delivered only to R1 resection
patients. In the selective postoperative chemoradiation
arm, the local relapse rate was 21% compared to 9% in
the R0 patients treated with surgery alone [16]. In the
Dutch TME randomized trial, patients in the surgery
alone arm were treated with 50.4 Gy in 28 fractions
postoperatively if they had a positive resection margin.
Only 47% of the R1 resection patients received the
protocol prescribed postoperative radiation (45–60 Gy).
The local recurrence rate at 2-years was 17% in positive
margin patients with radiation and 16% in those who
did not receive radiation [17].
Because the volume of normal tissue included within
an IORT field is small and because sensitive and dose
limiting organs such as small intestine can be mobilized
out of the IORT field, there is a strong rationale for in-
vestigating IORT as a means of increasing the effective
radiation dose. In patients with locally advanced or re-
current colorectal cancer, IORT is considered when sur-
gery alone results in unacceptable local control and an
effective external beam dose in excess of 60–70 Gy is re-
quired for local control. IORT is delivered at the time of
a planned operative procedure and is typically limited to
patients without metastatic disease or patients with lim-
ited volume metastatic disease being treated with cura-
tive intent.
IORT for colon cancer
Most patients with colon cancer are adequately treated
with surgery with or without adjuvant systemic therapy.
There is no established role for the routine use of radi-
ation as an adjuvant therapy in colon cancer. An inter-
group study (0130) evaluated the use of 5-fluorouracil
(5-FU) and levamisole with or without adjuvant radi-
ation in colon cancer patients following R0 resection.
Eligible patients included those with tumor adherence or
invasion of surrounding structures or those with T3N+
tumors of the ascending or descending colon. The radi-
ation dose was 45–50.4 Gy in 1.8 Gy fractions. Although
the study closed early with only 222 out of a planned
700 patients accrued and only 187 evaluable patients,
the was no difference in survival, disease-free survival or
local control with the addition of radiation therapy [18].
Although radiation therapy is not routinely indicated
for colon cancer patients, there may be a role in patients
with locally advanced disease that is not amenable or is
unlikely to be amenable to R0 resection or in patients
with local recurrence in retroperitoneal locations. Recur-
rent patients that may benefit include tumor bed recur-
rences as well as locally advanced nodal recurrences. In
these groups of patients IORT has been investigated.
Primary locally advanced colon cancer
IORT as a component of therapy for locally advanced
colon cancer began to be investigated at Mayo Clinic in
1981. Schield et al. reported a series of 103 patients
treated from 1974 to 1994, about half of whom were
subtotally resected [3]. These patients were generally
treated with postoperative external beam radiation
(EBRT) with 5-FU. The median EBRT dose was 50.4 Gy
in 28 fractions and all but 3 patients received between
40 and 60 Gy. Eleven patients, nine of whom were sub-
totally resected received IORT with a median dose of
15 Gy (range, 10–20 Gy). Results are summarized in
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Table 1. Resection margins were strongly correlated with
disease relapse and survival. Escalation of the EBRT dose
above 50 Gy was not associated with improved disease
control or survival, but was associated with a 19% small
bowel obstruction rate compared to 9% with 50 Gy or
less (p = 0.08). Although the number of IORT patients
was small, there was a statistically significant improve-
ment in local control, distant control and survival in
subtotally resected patients who received IORT in
addition to EBRT.
In a follow-up series from the Mayo Clinic, Mathis et
al. reported results of multimodal therapy including
IORT in 146 unresectable T4 colorectal cancers treated
between 1981 and 2007 [6]. A subset of 40 patients had
tumors located in the colon. EBRT was generally deliv-
ered preoperatively to a median dose of 50.4 Gy in 28
fractions. The median IORT dose was 12.5 Gy. Five year
local control was 86% in the entire group and in the sub-
set of 40 patients with colon cancer, the median survival
was 7.2 years with a 5-years survival rate of 61%. Of
note, in the entire group of patients, adjuvant chemo-
therapy with FOLFOX or FOLFIRI was associated with a
92% 5-year survival.
Locally advanced recurrent colon cancer
Results of multimodality therapy including IORT for lo-
cally advanced recurrent colorectal cancer were reported
in a Mayo Clinic series of 607 patients in 2011 [19]. This
series included 180 patients with recurrent colon cancer
treated between 1981 and 2008. EBRT was generally de-
livered preoperatively (median 45 Gy) with 5-FU and the
median IORT dose was 15 Gy. About two thirds of the
entire group of patients was subtotally resected and in
this group central relapse within the IORT field was ob-
served in only 16% of patients at 5 and 10 years. For the
subset of 180 recurrent colon cancer patients, the ob-
served 5-year survival was 34%.
IORT for advanced regional nodal disease in colon
cancer patients
Patients with locally advanced retroperitoneal nodal dis-
ease may represent a relatively favorable subset of colon
cancer patients with treated with multimodality therapy.
IORT as a component of therapy in colon cancer pa-
tients with advanced nodal disease has been evaluated in
a Mayo Clinic series. Thirty-seven patients were treated
between 1981 and 2000, prior to the modern chemother-
apy era. Advanced nodal recurrence, defined as disease
unlikely to be controlled with surgery alone, was present
in 31 patients while 6 had advanced nodal disease at pri-
mary presentation. Patients were typically treated with
50.4 Gy in 28 fractions preoperatively with 5-FU. IORT
was delivered with 9–15 MeV electrons to a median
dose of 12.5 Gy. For the entire group, 5-year survival
was 40% with 3-year local relapse in 14%, distant relapse
in 36% and central relapse in the IORT field in only 7%.
For the subset of patients without gross residual disease
(R0 or R1 resection), the 5-year survival was 49% with a
median survival of 53 months [20].
IORT for rectal cancer
Primary locally advanced rectal cancer
Most patients with locally advanced rectal cancer are
not likely to benefit from a dose escalation approach
using IORT. In a pooled analysis of 5 North American
adjuvant rectal cancer studies, standard chemoradiation
was associated with a less than 10% risk of local relapse
in patients with a single risk factor of T3N0 disease or
T1-2 N1 disease [21]. Among patients with T4 node
positive disease, however, local relapse was observed in
20–30% of patients treated with standard chemoradia-
tion following R0 resection. The MERCURY study group
reported a favorable subset of T3 rectal cancers based
on MRI staging to include patients with less than 5 mm
extramural spread, no abutment of mesorectal fascia and
no extramural venous invasion or invasion of the inter-
sphincteric plane for low tumors [21]. This group had a
local recurrence rate of less than 2% without the use of
any radiation therapy.
Selection of patients is a key factor for appropriate use
of IORT in the primary setting. Patients who may bene-
fit are those with T4 primaries in whom R0 resection is
unlikely with surgery alone. The only modern prospect-
ive study of IORT for primary rectal cancer was con-
ducted in patients unlikely to benefit from dose
escalation. A French multicenter phase III trial con-
ducted from 1993 to 2001 randomized patients treated
with preoperative EBRT to IORT or observation at the
time of resection [22]. Eligible patients were patients
Table 1 Disease control and survival in locally advanced colon
cancer, Mayo Clinic results
Group # Patients 5-year LR 5-year DM 5-year OS
R0 resection 50 10% ~30% 66%
R1 resection 18 54% ~57% 47%
R2 resection 35 79% ~68% 23%
p < 0.0001 p = 0.002 p = 0.0009
EBRT > 50 Gy 73 36% - 50%
EBRT≤ 50 Gy 30 50% - 45%
p = 0.18 p = 0.16
R1-2 + IOERT 9 11% ~12% 76%
R1-2, no IOERT 44 82% ~76% 26%
p = 0.02 p = 0.01 p = 0.04
Abbreviations: EBRT external beam radiation therapy, LR local relapse,
DM distant metastases, OS overall survival, IOERT intraoperative electron
radiation therapy
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with T3 or T4 primary rectal cancer or node positive
rectal cancer. Ninety percent of the patients on the study
were T3 and 66% were node negative. The preoperative
radiation dose was 40 Gy in 20 fractions and the IORT
dose was 18 Gy. Local control at 5-years was observed
in 93% of patients without IORT and 92% with IORT.
There was no significant difference in distant relapse,
disease-free survival, overall survival or toxicity between
the treatment groups.
IORT may be appropriate for R0 resection patients
when margins are close or when there has been response
to preoperative chemoradiation that may leave margins
at risk for harboring undetectable residual disease. Re-
sults of selected series of IORT for primary rectal cancer
are presented in Table 2. With modern imaging tech-
niques, patients at risk for potential subtotal resection
should be identified preoperatively and treated with neo-
adjuvant chemoradiation. The most common regimen is
45–50 Gy in 1.8–2 Gy fractions with concomitant 5-FU
or capecitabine. Surgery is typically done 4–8 weeks
after the completion of radiation and the IORT dose has
generally been in the range of 10–20 Gy. Local control
in the EBRT field is above 85% in nearly all series.
Distant relapse is reported in 25–50% of patients and
reported 5-year survival ranges from 50–80%.
Several factors have been reported to be related to dis-
ease control and survival. The most consistently re-
ported factor is the completeness of the surgical
resection, a factor related to both surgical quality and
biology. Even with the addition of IORT, a margin posi-
tive resection is associated with a 5-fold increase in the
risk of locoregional relapse and increased risk of death
[23, 24]. Despite this, local control is maintained in most
patients with the addition of IORT even after R2 resec-
tion. In the MGH series the reported local control in
patients with gross residual disease was 57% and in the
Mayo Clinic series it was 73% [25, 26]. This is perhaps
the strongest evidence suggesting a benefit for dose es-
calation with IORT.
Additional factors related to survival and disease con-
trol include timing of EBRT and chemotherapy use. Pre-
operative chemoradiation is preferred in the adjuvant
treatment of rectal cancer based on improved local con-
trol and reduced toxicity [27]. In the Mayo IORT series,
preoperative sequencing was also associated with im-
proved survival (55% vs 38% 5-year) [27]. Because the
predominant failure pattern in IORT series is distant re-
lapse, effective systemic therapy is critical for survival
improvements. The addition of 5-FU to EBRT was asso-
ciated with a reduction in distant relapse (83% vs 41% 5-
year) in the Mayo Clinic series and the administration of
systemic adjuvant chemotherapy has been associated
with improved survival in multiple series [6, 24, 26].
Recurrent rectal cancer
Although improvements in surgical technique (total
mesorectal excision) and neoadjuvant therapy have sig-
nificantly reduced the incidence of pelvic recurrence of
rectal cancer, management of local recurrence remains
problematic. Failure to control pelvic recurrence leads to
pain, bleeding, urinary and rectal obstruction and can be
the cause of death even in the absence of distant meta-
static disease. With the possible exception of early anas-
tomotic recurrences limited to the bowel wall that can
be cured with resection alone, control of locally recur-
rent cancer requires multimodality therapy [28].
In an early Mayo Clinic experience, subtotal resection
alone resulted in no 5-year survivors and the addition of
moderate dose EBRT (median 50.4 Gy) resulted in 7% 5-
year survival [4].
Table 2 Disease control and survival with IORT for locally advanced rectal cancer. Results of selected series
Study # Patients Years EBRT dose, Gy Margins IORT dose, Gy 5-year LC 5-year DM 5-year OS
Willett, MGH [42] 20 1978–1989 50.4 R0 10–20 88% - 53%a
Valentini, Rome [43] 29 1991–2006 45–55 R0 10–15 100% - -
Alberda, Rotterdam [44] 31 1996–2012 45–50b R1 10c 84% - -
Zhang, Shanghai [45] 71 1994–2007 45–50.4 R0-1 10–20 90% 54% 75%
Sadahiro, Japan [46] 99 1991–2001 20 ns 15–25 98% 20% 79%
Mathis, Mayo Clinic [6] 106 1981–2007 50.4 R0-2 7.5–25 86%d 49%d 49%
Roeder, Heidelberg [47] 243 1991–2004 41.4 R0-2 10–15 92% - -
Sole, Madrid [23] 335 1995–2010 45–50.4 R0-1 10–15 92% 25%e 75%
Kusters, European pooled [24] 605 to 2005 45–50.4 R0-2 10–12.5 88% 29% 67%
Abbreviations: IORT intraoperative radiation therapy, LC local control, DM distant metastases, OS overall survival, EBRT external beam radiation therapy, MGH
Massachusetts General Hospital
aDisease-free survival
bSome patients treated with 25 Gy in 5 fractions
cintraoperative high dose rate brachytherapy
dincludes 40 colon primary patients
ecrude
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As is the case with primary rectal cancer, the most im-
portant factor associated with disease control and sur-
vival in IORT series is the completeness of surgical
resection [19, 29–34]. Results of selected series including
IORT for locally recurrent rectal cancer following R0, R1
and R2 resection are presented in Tables 3, 4 and 5. In
patients in whom an RO resection can be accomplished,
IORT is associated with local control in 60–80% of pa-
tients and 5-year survival in 40–50% of patients. When
margins are microscopically positive, local control is in
the range of 30–60% and 5-year survival is reported in
20–30%. In the case of gross residual disease, local
control is in the range of 30–50% and 5-year survival is
reported in 15–25%. Distant relapse is reported in more
than 70% of patients if resection is macroscopically
incomplete. Although there are no randomized com-
parisons, the results for incompletely resected patients
appear to be an improvement over surgery with or
without EBRT. In the Mayo Clinic series of palliative
resection patients, 3-year survival was 44% and local re-
lapse 40% in R2 patients who received IORT compared
to 15% 3-year survival and 93% local relapse in non-
IORT patients [4].
Previously irradiated patients
A particularly challenging group of patients with locally
recurrent rectal cancer are those who have previously re-
ceived a course of radiation as adjuvant therapy for their
primary malignancy or for another primary malignancy.
Because of an increased risk of complications in these
patients, the use of IORT without additional EBRT has
been explored, but results have been poor. A Pamplona
series reported the results of 10–20 Gy IORT in pelvic
recurrences of rectal cancer with or without EBRT. Local
control at 3-years was 0% with IORT alone and 30% with
EBRT + IORT and survival improved from 12 to 38%
with the addition of EBRT [35]. Similarly, a Lyon series
reported on 50 patients treated with 10–25 Gy IORT
with or without EBRT [36]. EBRT was withheld due to
prior radiation or postoperative complications. Three
year survival was 68% and local control 61% for the
combination of EBRT and IORT versus 25% survival and
0% local control for IORT alone.
Despite the risk of late toxicity in previously irradiated
patients, additional EBRT can be delivered to most
patients with acceptable morbidity. In general, re-
irradiation targets are limited to the gross tumor volume
without inclusion of elective target volumes and with ex-
clusion of all small bowel. In a University of Kentucky
series, 103 previously irradiated rectal cancer patients
received a 2nd course of EBRT to a median dose of
34.8 Gy with 5-FU [37]. Only 34 of these patients also
had a surgical resection. Although not insignificant,
complications in 21% of patients including chronic se-
vere diarrhea in 17% and small bowel obstruction in 15%
were felt to be acceptable. A phase II study conducted in
Rome included 59 previously irradiated recurrent rectal
cancer patients who were treated with a second course
of EBRT to a dose of 40.8 Gy in 1.2 Gy bid fractions
with 5-FU [38]. In this series in which the target was
limited to gross disease, late toxicity was mild with only
one late small bowel obstruction.
Since the original publication of the University of
Kentucky series [39], previously irradiated patients at
Mayo Clinic have been re-irradiated to a dose of 30 Gy
over 3 weeks with 5-FU immediately prior to surgery
and IORT. Tumor volumes have been limited to gross
disease with a small margin. Re-irradiation has been lim-
ited to the preoperative setting which allows much of
the heavily irradiated volume to be removed. Although
local relapse remains higher in previously irradiated pa-
tients (37% vs 22% at 5-years) [19], these results are
much improved compared to results with IORT alone.
Similarly, in the Eindhoven experience, improved results
Table 3 Disease control and survival with IORT for locally recurrent rectal cancer in association with R0 resection. Results of selected series
Study Years # Patients EBRT dose, Gy IORT dose, Gy IORT technique 5-year LC 5-year DM 5-year OS
Alektiar, MSKCC [30] 1992–1998 53 50.4a 10–18 IOHDR 43% - 36%
Lindel, MGH [31] 1978–1997 25 50.4b 10–15 IOERT 56% - 40%
Wiig, Norway [33] 1990–1999 18 46–50 15–20 IOERT 70% - 60%
Eble, Heidelberg [33] c 1991–1995 14 41.4 10–20 IOERT 79% 19% 71%d
Dresen, Eindhoven [34] 1994–2006 84 50.4e 10 IOERT 69% 34% 48%
Haddock, Mayo Clinic [19] 1981–2008 236 50.4f 12.5 IOERT 79% 48% 46%
Abbreviations: R0 pathologically negative margins, EBRT external beam radiation therapy, IORT intraoperative radiation therapy, LC local control, DM distant
metastases, OS overall survival, MSKCC Memorial Sloan Kettering Cancer Center, MGH Massachusetts General Hospital, IOHDR Intraoperative high dose
rate brachytherapy
a50.4 in patients with no prior EBRT; no EBRT in patients with prior radiation
b20–50 Gy in previously irradiated patients
c4-year results
d4-year relapse free survival
e30.6 Gy in previously irradiated patients
f5–39.6 Gy in previously irradiated patients
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were noted in previously irradiated patients after the
addition of preoperative EBRT to a dose of 30.6 Gy.
With IORT alone, survival at 3-years was 25% and
local control 38%. After the addition of re-irradiation,
the 3-year survival improved to 48% and local control
to 49% [34].
IORT toxicity
Patients with very locally advanced primary and recur-
rent rectal cancer often experience significant tumor re-
lated and treatment related toxicity. Most treatment
related effects are multifactorial and it is often difficult
to attribute toxicity to a single modality. In a systematic
review of 29 published studies including 3003 patients
with locally advanced primary or recurrent colorectal
cancer, IORT was associated with a significant improve-
ment in local control and survival without an increase in
total, urologic or anastomotic complications [40]. There
was, however, an increased risk of wound complications
following IORT. Wound infections and pelvic abscess
are common complications reported in 25% or more of
IORT patients in several series [30, 33, 34, 41]. In the
Mayo Clinic series, the incidence of severe, life-
threatening or fatal wound infection or abscess was 13%
regardless of attribution with a rate of 7% potentially at-
tributable to IORT [19].
With the addition of IORT to EBRT, the dose limiting
normal tissue is typically peripheral nerve and neur-
opathy is the most commonly reported toxicity attrib-
uted to IORT in the pelvis. IORT related neuropathy
most commonly manifests as pain without weakness or
sensory loss. When it occurs, the pain is often chronic
and may be severe, but often is manageable with gaba-
pentin or pregabalin. Both the incidence and severity of
IORT related neuropathy appear related to IORT dose.
Even in previously irradiated patients, neuropathy inci-
dence is related to IORT dose and not the total cumula-
tive dose including EBRT. In the Mayo Clinic series, in
the primary setting an IORT dose of 12.5 Gy or less was
associated with a 3% incidence of grade 2 (requiring nar-
cotics) or grade 3 (intractable pain) neuropathy while
IORT doses of 15 Gy or higher were associated with a
23% incidence of grade 2–3 neuropathy [26]. In the lo-
cally recurrent disease setting, IORT doses of 12.5 Gy or
Table 4 Disease control and survival with IORT for locally recurrent rectal cancer in association with R1 resection. Results of
selected series
Study Years # Patients EBRT dose, Gy IORT dose, Gy IORT technique 5-year LC 5-year DM 5-year OS
Alektiar, MSKCC [30] 1992–1998 21 50.4a 10–18 IOHDR 26% - 11%
Wiig, Norway [33] 1990–1999 29 46–50 15–20 IOERT 50% - 20%
Eble, Heidelberg [33]b 1991–1995 9 41.4 10–20 IOERT 67% 33% 33%c
Dresen, Eindhoven [34]f 1994–2006 34 50.4d 12.5 IOERT 29% 69% 27%
Haddock, Mayo Clinic [19] 1981–2008 224 50.4e 15 IOERT 56% 62% 27%
Abbreviations: R1 microscopic residual disease, EBRT external beam radiation therapy, IORT intraoperative radiation therapy, LC local control, DM distant
metastases, OS overall survival, MSKCC Memorial Sloan Kettering Cancer Center, IOHDR intraoperative high dose rate brachytherapy
a50.4 in patients with no prior EBRT; no EBRT in patients with prior radiation
b4-year results
c4-year relapse free survival
d30.6 Gy in previously irradiated patients
e5–39.6 Gy in previously irradiated patients
f3-year results
Table 5 Disease control and survival with IOERT for locally recurrent rectal cancer in association with R2 resection. Results of
selected series
Study Years # Patients EBRT dose, Gy IORT dose, Gy 5-year LC 5-year DM 5-year OS
Lindel, MGH [31] 1978–1997 15 50.4a 15–20 12% - 13%
Eble, Heidelberg [33]b 1991–1995 8 41.4 10–20 60% 75% 25%c
Dresen, Eindhoven [34] 1994–2006 29 50.4d 15–17.5 29% 71% 24%
Haddock, Mayo Clinic [19] 1981–2008 156 50.4e 20 49% 73% 16%
Abbreviations: R2 gross residual disease, EBRT external beam radiation therapy, IOERT intraoperative electron radiation therapy, LC local control, DM distant
metastases, OS overall survival, MSKCC Memorial Sloan Kettering Cancer Center, MGH Massachusetts General Hospital,IOHDR intraoperative high dose
rate brachytherap
a20–50 Gy in previously irradiated patients
b4-year results
c4-year relapse free survival
d30.6 Gy in previously irradiated patients
e5-39.6 Gy in previously irradiated patients
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less were associated with a 5% incidence of grade 2–3
neuropathy compared to 14% for IORT doses of 15 Gy
or higher [19].
Conclusions
Intraoperative radiation is a useful tool for dose escal-
ation in patients with locally advanced primary and re-
current rectal cancer. It should be combined with
preoperative EBRT and 5-FU or capecitabine. For pa-
tients with locally advanced primary or recurrent disease
amenable to complete resection, the benefit of dose es-
calation with IORT should be prospectively evaluated.
For subtotally resected patients, despite the lack of con-
trolled trials, the body of available evidence strongly sug-
gests that dose escalation with IORT in addition to
EBRT and chemotherapy increases the likelihood of dis-
ease control and survival. Previously irradiated patients
with local recurrence can often be safely re-irradiated
and should receive preoperative EBRT with 5-FU or cap-
ecitabine. IORT doses of 15 Gy or higher appear to be
associated with an increased risk of neuropathy. Distant
relapse remains a significant challenge, but with the sig-
nificant survival gains obtained with systemic therapy in
the metastatic disease setting, long term control of pelvic
disease has become even more important.
Abbreviations
DM: Distant metastases; EBRT: External beam radiation therapy;
IOERT: Intraoperative electron radiation therapy; IOHDR: Intraoperative high
dose rate brachytherapy; IORT: Intraoperative radiation therapy; LC: Local
control; MGH: Massachusetts General Hospital; MSKCC: Memorial Sloan
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